Table 1.
List of transplant patients from our cohort.
| Sample ID | Age | Sex | Ethnicity | Comorbidities | Invasive mechanical ventilation/ECMO | COVID specific treatments | Day of transplant from positive PCR |
|---|---|---|---|---|---|---|---|
| TXC1 | 69 | M | H | HTN, DM II | No | Convalescent plasma, dexamethasone, remdesivir | 57 |
| TXC2 | 63 | M | C | HTN | No | Convalescent plasma, dexamethasone, remdesivir | 68 |
| TXC3 | 46 | F | H | None | No | Dexamethasone | 139 |
| TXC4 | 52 | M | H | None | Yes/Yes | Convalescent plasma, dexamethasone, remdesivir | 90 |
| TXC5 | 16 | M | H | None | Yes/Yes | Convalescent plasma, dexamethasone, remdesivir, IVIG | 127 |
| TXC6 | 42 | F | H | Thrombotic Thrombocytopenic Purpura on Rituxan | Yes/Yes | Dexamethasone, remdesivir | 86 |
| TXC7 | 33 | M | C | HTN | Yes/Yes | Convalescent plasma, dexamethasone, remdesivir | 180 |
| TXC8 | 24 | M | C | None | Yes/Yes | Dexamethasone, remdesivir | 55 |
| TXC9 | 53 | M | H | DM II, HTN, HLD, Obesity | No/Yes | Dexamethasone, remdesivir, convalescent plasma | 143 |
| TXC10 | 40 | M | H | None | Yes/Yes | Remdesivir, convalescent plasma, dobutamine, NO, epoprostenol | 106 |
| TXC11 | 43 | M | H | DM II, HTN, Morbid Obesity | Yes/Yes | Remdesivir, convalescent plasma, dexamethasone, levaquin | 74 |
| TXC12 | 54 | M | AA | None | Yes/Yes | Remdesivir, dexamethasone, Azithromycin | 110 |
| TXC13 | 60 | M | H | HTN | Yes/Yes | Dexamethasone | 143 |
| TXC14 | 37 | M | AA | HTN, DM II | Yes/Yes | Remdesivir, dexamethasone | 126 |
| TXC15 | 34 | M | As. | None | Yes/Yes | Dexamethasone, convalescent plasma | 189 |
| TXC16 | 42 | M | H | Obesity, dyslipidemia | Yes/Yes | Remdesivir, dexamethasone | 146 |
| TXC17 | 63 | M | H | GERD, Hypothyroidism, allergies, Previous hospitalization for COVID w/ Discharge | Outpatient | Monoclonal antibodies, remdesivir, dexamethasone, azithromycin/ rocephin | 211 |
| TXC18 | 58 | M | H | DM, HTN | No/No | Convalescent plasma, dexamethasone, remdesivir | N/A |
| TXC19 | 32 | M | H | Obesity | Yes/Yes | Convalescent plasma, dexamethasone, remdesivir, Ruxolitnib | N/A |
| TXC20 | 55 | M | H | Obesity, CAD, anxiety, DM II, HTN, HLD | No/No | Decadron, remdesivir, convalescent plasma | 91 |
| TXC21 | 60 | F | C | Obesity, HTN, HLD, DM II, anxiety, GERD | No/No | Convalescent plasma RemDex, steroids | 136 |
| TXC22 | 47 | F | C | None | Yes/Yes | Steroids, remdesivir, tocilizumab, baricitinib | 57 |
| TXC23 | 52 | M | C | Smoking, heroin, RB-ILD | Yes/Not | Uncertain | 168 |
| Average | 46.7 | 119 |
All the patients underwent lung transplantation between July 2020 and July 2021. Hospital course was best established in 19 of the 23 patients. We recorded demographics and treatment for our study. AA = African American, As. = Asian, C = Caucasian, H = Hispanic When available, mean time from PCR positivity to lung transplant was recorded (range 55–211). Hypertension (HTN), diabetes mellitus type two (DM II), hyperlipidemia (HLD), gastroesophageal reflux disease (GERD), coronary artery disease (CAD), respiratory bronchiolitis-interstitial lung disease (RB-ILD).